Skip to main content
Fig. 1 | BMC Cancer

Fig. 1

From: Efficacy, safety and biomarker analysis of durvalumab in patients with mismatch-repair deficient or microsatellite instability-high solid tumours

Fig. 1

Treatment efficacy of durvalumab. Swimmer plot of the time on treatment (in months) for each evaluable patient (n = 24). Patients marked with an arrow were still on study (as per December 16th, 2021). The red dot marks treatment discontinuation. The diamond-shape marks partial responses (PR) and the asterisk marks complete responses (CR)

Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us